Phage Therapy Patents

Bacteriophage (phage) therapy patents cover engineered/synthetic-phage innovations; phage-cocktail and host-range innovations; phage-banking and strain-matching innovations; and manufacturing, delivery, and CRISPR-armed innovations — with IP held by phage-therapy companies and engineered-microbial firms (in a field using bacteria-killing viruses as an alternative/complement to antibiotics for antimicrobial-resistant (AMR) infections). WHY PHAGE THERAPY: antibiotic resistance (AMR) is a growing crisis with few new antibiotics; bacteriophages are viruses that infect and kill SPECIFIC bacteria — highly targeted (sparing the microbiome), self-amplifying at the infection site, and effective against antibiotic-resistant strains, and they can be ENGINEERED for expanded host range and added functions. MAJOR PHAGE-THERAPY PATENT HOLDERS: ARMATA PHARMACEUTICALS: natural and synthetic phage for resistant infections (e.g., Pseudomonas, Staph). LOCUS BIOSCIENCES: crPhage — phage engineered to deliver CRISPR-Cas3 that shreds target bacterial DNA (combining phage killing + CRISPR). SNIPR BIOME: CRISPR-armed phage targeting specific bacteria. BIOMX: engineered phage for disease/microbiome. ADAPTIVE PHAGE THERAPEUTICS: PhageBank — a library matched to a patient's strain (personalized). FELIX BIOTECHNOLOGY, ELIGO BIOSCIENCE, and academic centers. Engineered/synthetic phage, cocktails/host-range, banking/matching, and CRISPR-arming are the core phage-therapy patent domains — and engineered host-range, resistance-robust cocktails, CRISPR-arming, and manufacturing/regulatory paths are the open whitespace.

Engineered/synthetic-phage innovations; host-range-engineering innovations; CRISPR-armed and payload innovations; and anti-virulence and lysis innovations represent core phage-therapy patent domains — and engineering a phage to kill a broader, more useful range of bacteria (and to do more than just lyse) is the central innovation frontier. ENGINEERED / SYNTHETIC-PHAGE PATENTS: rationally engineering or fully synthesizing phage genomes — modifying the phage to improve killing, reduce immunogenicity, remove toxin/lysogeny genes, and create defined synthetic phage (vs isolated natural phage); the engineered phage genome and specific modifications are composition-of-matter IP. HOST-RANGE-ENGINEERING PATENTS: expanding or redirecting which bacteria a phage infects — engineering receptor-binding proteins/tail fibers to broaden host range or retarget to a specific strain (natural phages are often too narrow); host-range engineering is high-value because narrow host range limits utility. CRISPR-ARMED / PAYLOAD PATENTS: using phage to DELIVER a payload into bacteria — CRISPR-Cas3 (Locus) or Cas9 that cuts the target bacterial genome to kill it sequence-specifically, or to remove resistance/virulence genes (SNIPR) — combining phage targeting + programmable nuclease killing; this is a major engineered-phage frontier. ANTI-VIRULENCE / LYSIS PATENTS: engineered phage or phage-derived lysins (enzymes that break bacterial walls) as antibacterials, and lytic-cycle control. Engineered host range (receptor/tail-fiber), CRISPR-armed sequence-specific killing, and synthetic defined phage are the highest-value engineered-phage IP because they overcome natural phages' narrow range and add programmable function.

Phage-cocktail and resistance-management innovations; phage-banking and strain-matching innovations; manufacturing and purification innovations; and delivery and formulation innovations represent additional phage-therapy patent domains — and managing bacterial resistance, matching phage to patient, and manufacturing pure clinical-grade phage are where the practical and regulatory value sits. PHAGE-COCKTAIL / RESISTANCE-MANAGEMENT PATENTS: combining multiple phages (with different bacterial receptors) so bacteria can't easily resist all at once — cocktail composition, phages that bind receptors tied to virulence (so resistance costs the bacterium fitness), and phage-antibiotic synergy; resistance management is the central efficacy challenge. PHAGE-BANKING / STRAIN-MATCHING PATENTS: maintaining a characterized library (bank) of phages and rapidly MATCHING the right phage(s) to a patient's specific bacterial isolate (Adaptive PhageBank) — the bank, the matching/susceptibility-testing method, and the personalized-supply model; this enables personalized phage therapy. MANUFACTURING / PURIFICATION PATENTS: producing clinical-grade phage — propagation on host bacteria, ENDOTOXIN and host-debris removal (critical for safety, phages are grown in bacteria), purity, titer, and GMP/stability; purification is a key CMC challenge. DELIVERY / FORMULATION PATENTS: delivering phage to the infection site (IV, inhaled for lung, topical, oral/encapsulated for gut), protecting phage stability, and overcoming immune neutralization. REGULATORY-MODEL PATENTS/strategy: personalized (matched, individualized) vs fixed defined cocktail — a defined product is more conventionally approvable. Resistance-robust cocktails, rapid strain-matching/banking, and endotoxin-free scalable manufacturing are the highest-value practical phage IP because resistance, matching, and purity determine clinical success and approvability.

Phage therapy startup IP strategy must navigate Armata/Locus/SNIPR engineered-phage and CRISPR-arming patents, a century of phage prior art (phages were used therapeutically since the 1920s, especially in Eastern Europe — natural phages and basic phage therapy are largely public-domain/prior-art), the resistance-management and narrow-host-range challenges, the manufacturing/purity (endotoxin) and regulatory-path realities (personalized vs defined product), and a landscape where engineered phage, cocktails, banking/matching, CRISPR-arming, and manufacturing are the durable assets; understand that natural phages and basic phage therapy are old/public, so the durable IP is in ENGINEERED phage (host range, synthetic genomes, CRISPR-arming), resistance-robust cocktails, banking/matching methods, and endotoxin-free manufacturing, and that resistance management, manufacturing purity, and the regulatory path matter as much as patents; identify whitespace in host-range engineering, CRISPR-arming, and defined approvable products. PHAGE-THERAPY STARTUP IP STRATEGY: NATURAL PHAGES ARE OLD/PUBLIC — ENGINEERING, COCKTAILS, AND METHODS ARE THE IP: a natural isolated phage is hard to protect (century of prior art), so patent ENGINEERED/synthetic phage, host-range engineering, CRISPR-arming, cocktail compositions, banking/matching methods, and manufacturing — not 'a phage that kills X'; ENGINEERED HOST RANGE AND CRISPR-ARMING ARE HIGH-VALUE WHITESPACE: broadening/retargeting host range and arming phage with CRISPR-Cas (Locus/SNIPR) overcome natural limits and add programmable, patentable function — the most defensible composition IP; RESISTANCE-ROBUST COCKTAILS ARE CENTRAL TO EFFICACY: multi-phage cocktails (diverse receptors, virulence-linked targets, phage-antibiotic synergy) manage resistance — cocktail composition and design are valuable; BANKING/MATCHING ENABLES PERSONALIZED THERAPY: a characterized phage bank + rapid strain-matching (Adaptive PhageBank) is a defensible method and supply model; ENDOTOXIN-FREE MANUFACTURING IS A CMC GATE: phages grown in bacteria need rigorous endotoxin/debris removal — purification IP is commercially decisive and safety-critical; REGULATORY PATH SHAPES STRATEGY (PERSONALIZED VS DEFINED): individualized matched phage is flexible but regulatorily novel; a fixed defined cocktail is more conventionally approvable — choose deliberately; WHEN TO PATENT: NOVEL ENGINEERED PHAGE/COCKTAIL/METHOD WITH MEASURED ACTIVITY: file once a phage/cocktail/method shows measured results (bacterial killing/host range + resistance-emergence rate + cocktail breadth + manufacturing purity (endotoxin/titer) + strain-match success + in vivo efficacy) vs. antibiotic/natural-phage baselines — measured host range, resistance robustness, and manufacturing purity are the critical phage IP metrics; KEY FTO CHECKLIST: Armata synthetic/natural phage; Locus crPhage CRISPR-Cas3 engineered; SNIPR CRISPR-armed phage; BiomX engineered phage; Adaptive PhageBank banking/matching; engineered/synthetic phage genome modification; host-range receptor-binding/tail-fiber engineering; CRISPR-Cas3/Cas9 bacterial-killing payload; anti-virulence/lysin enzyme; phage cocktail receptor-diversity/phage-antibiotic synergy; manufacturing propagation/endotoxin-removal/purity/titer; delivery IV/inhaled/oral-encapsulated formulation; century of phage prior art (public domain); personalized vs defined-cocktail regulatory.